However, except for rivastigmine, which is a dual acetylcholinesterase-butyrylcholinesterase inhibitor, approved selective acetylcholinesterase inhibitor drugs are not suitable for late-stage Alzheimer’s disease since acetylcholine hydrolysis in the late stage of the disease mainly depends on butyrylcholinesterase but not acetylcholinesterase [11]. This evidence concerns the gene BCHE and Alzheimer disease.